Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00395_DB00705_nanopub.RAzxcmZLQ84GVMhEd-EYy9attylIpOBRG5WPDhxEJ-8O0#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00395_DB00705 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00395_DB00705 label "DDI between Carisoprodol and Delavirdine - Strong CYP2C19 inhibitors such as delavirdine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased. [drugbank_resource:DB00395_DB00705]" assertion.
- drugbank_resource:DB00395_DB00705 identifier "drugbank_resource:DB00395_DB00705" assertion.
- drugbank_resource:DB00395_DB00705 title "DDI between Carisoprodol and Delavirdine - Strong CYP2C19 inhibitors such as delavirdine may decrease the metabolism of CYP2C19 substrates such as carisoprodol. Consider an alternative for one of the interacting drugs in order to avoid toxicity of the substrate. Some combinations are specifically contraindicated by manufacturers. Suggested dosage adjustments are also offered by some manufacturers. Please review applicable package inserts. Monitor for increased effects of the CYP substrate if a CYP inhibitor is initiated/dose increased, and decreased effects if a CYP inhibitor is discontinued/dose decreased." assertion.
- drugbank:DB00705 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00395_DB00705 assertion.
- drugbank:DB00395 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00395_DB00705 assertion.